ESR1 and neoplasm: The multivariable analysis in all patients adjusting for tumor size, tumor grade, ER, PR, HER2, Ki67, and TAM treatment showed that high TILs (≥40%) significantly reduced the risk of distant recurrences with a 53% risk reduction (HR (95% CI) = 0.47 (0.24–0.95)), but not when limiting the analysis to the ER+/HER2− or any other specific IHC subtype (Table 2 and Table S2).